di-tert-butyl dicarbonate | 118119-47-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: di-tert-butyl dicarbonate
• 英文别名: 2-O-tert-butyl 1-O-[2-[(2-methylpropan-2-yl)oxy]-2-oxoacetyl] oxalate
• CAS: 118119-47-4
• 化学式: C₁₂H₁₈O₇
• 分子量: 274.271
• InChiKey: VVXJCYNUHWPCNJ-UHFFFAOYSA-N

物化性质

• 沸点：
  319.0±25.0 °C(Predicted)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.74
• 重原子数：
  19.0
• 可旋转键数：
  0.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  95.97
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  di-tert-butyl dicarbonate 在 4-二甲氨基吡啶 、 N,N-di-(2,6-diisopropyl)-1,6,7,12-tetrabromo-2,5,8,11-tetracyano-perylen-3,4,9,10-tetracarboxylic acid imide 作用下， 以 乙腈 为溶剂， 反应 65.0h， 生成 tert-butyl N-(2-methoxyethyl)-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate
  参考文献：
  名称：

  贫电子苝双酰亚胺光氧化还原催化从烯酰胺制备 N,O-缩醛

  摘要：

  仅使用缺电子苝双酰亚胺和光即可将烯酰胺转化为N , O-缩醛，无需苯硫酚作为添加剂或强酸作为催化剂。

  DOI：

  10.1002/chem.202400247

文献信息

• Synthesis and Cytotoxicity of the Proposed Structure of Piperazirum, Its Stereoisomers and Analogues
  作者：Gangarajula Sudhakar、Shruthi Bayya、Karla Janardhan Reddy、Balasubramanian Sridhar、Komal Sharma、Surendar Reddy Bathula

  DOI：10.1002/ejoc.201301435

  日期：2014.2

  biologically active alkaloid isolated from Arum palaestinum Bioss, is described, starting from commercially available α-amino acids. Two synthetic strategies were developed for the synthesis of the enantiomeric pair of compounds corresponding to the proposed structure of piperazirum. The first strategy was used in the synthesis of stereoisomers, and the second one was used in generating the analogues. The compounds

  Piperazirum 是一种从 Arum palaestinum Bioss 中分离出的新的生物活性生物碱，从市售的 α-氨基酸开始。开发了两种合成策略，用于合成与所提出的哌嗪结构相对应的化合物对映体对。第一种策略用于合成立体异构体，第二种策略用于生成类似物。针对不同细胞系筛选合成的化合物以评估它们的细胞毒性特征。
• HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF
  申请人：HECKEL Armin

  公开号：US20130109697A1

  公开（公告）日：2013-05-02

  The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

  本发明涉及一般式（I）的化合物及其互变异构体和盐，特别是其与无机或有机酸和碱形成的药用盐，具有有价值的药理特性，特别是对上皮钠通道具有抑制作用，并且用于治疗疾病，特别是肺部和呼吸道疾病。
• Using <i>N</i>-Nitrosodichloroacetamides to Conveniently Convert Linear Primary Amines into Alcohols
  作者：Nicholas S. MacArthur、Linshu Wang、Blaine G. McCarthy、Charles E. Jakobsche

  DOI：10.1080/00397911.2015.1061672

  日期：2015.9.2

  The reported rearrangement of N-nitrosodichloroacetamides provides a practicalmethod for converting primary amines into primary alcohols. The reaction sequence is operationally simple, requires only a single purification, and is compatible with a number of common functional groups. Mechanistic studies of the nitrosylation and rearrangement reactions illustrate the increased utility of dichloroacetamides compared to various other amides for this transformation.
• Synthesis and structure of novel dinitrosyl iron complexes [Fe2(μ-SCH2CH2NHR)2(NO)4]
  作者：P. B. Davidovich、V. V. Gurzhy、A. N. Belyaev

  DOI：10.1134/s1070363214040203

  日期：2014.4

  Two novel dinitrosyl iron complexes with thiolate bridging ligands [Fe-2(mu-SCH2CH2NHR)(2)(NO)(4)] (R = Ac, Boc), derived from the cysteamine complex [Fe-2(mu-SCH2CH2NH3)(2)(NO)(4)](2+) are described. The complex with acylated cysteamine is characterized by X-ray diffraction analysis. The cysteamine complex is a convenient precursor for modification of the bridging ligand.
• Discovery of 5,7-Dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors
  作者：Alexander Sokolsky、Sarah Winterton、Keith Kennedy、Katherine Drake、Kristine Stump、Lu Huo、Yvonne Lo、Min Ye、Maryanne Covington、Sharon Diamond、Yan-ou Yang、Sunkyu Kim、Swamy Yeleswaram、Liangxing Wu、Wenqing Yao

  DOI：10.1021/acsmedchemlett.2c00408

  日期：2022.11.10